The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Recce Pharmaceuticals (RCE) reports no serious adverse effects from intravenously dosing the seventh cohort of its phase one clinical trial with 6000 milligrams of its R327 drug
  • As part of the trial, 10 healthy male subjects were dosed for over an hour, with the 6000-milligram dose marking a 120-fold increase on the first cohort of the trial
  • The latest trial data is now being reviewed by an Independent Safety Committee, which is expected to give Recce the green light to move forward and dose Cohort Eight with R327
  • The company says it has begun preparations for the next phase of the trial
  • Shares in Recce Pharmaceuticals last traded at 85.5 cents each on August 19

Recce Pharmaceuticals (RCE) has reported no serious adverse effects from intravenously dosing the seventh cohort of its phase one clinical trial with 6000 milligrams of its R327 drug.

As part of the trial, 10 healthy male subjects were dosed for over an hour, with the 6000-milligram dose marking a 120-fold increase on the first cohort of the trial, which received 50 milligrams of the treatment.

The latest trial data is now being reviewed by an Independent Safety Committee, which is expected to give Recce the green light to move forward and dose the eighth trial cohort with R327.

The company said it had begun preparations for the next phase of the trial.

CEO James Graham said he was “thrilled” to complete the round of dosing.

“Achieving a 120-fold increase from Cohort One, with anticipation to soon begin a Cohort Eight, continues to build the safety and tolerability profile as a potential new class of antiinfectives,” he said.

R327 is designed to treat serious bacterial infections including sepsis.

The company said the 6000-milligram dose was broadly in the efficacy range of the treatment based on previous animal models.

Shares in Recce Pharmaceuticals last traded at 85.5 cents each on August 19.

rce by the numbers
More From The Market Online

Market Close: ASX slides 1.58% as global AI sell-off rattles investors

My nerves, along with my portfolio, have taken a beating over the last couple of weeks – and I’m sick of seeing red!

Market Close: Materials drag ASX lower as seven sectors finish higher

The Australian share market finished lower on Monday, with weakness across the resources sector weighing on the broader market despite gains across most

Market Close: ASX slides as resources and miners lead broad market sell-off

The Australian sharemarket came under renewed pressure on Tuesday 17th Nov, with selling extending across almost every sector as resources and energy

Market Close: ASX slides as technology and materials stocks lead broad market decline

The Australian share market finished lower on Wednesday, with the S&P/ASX 200 falling 0.69% to close at 8,821.80 points.